Physicians; Nurse Practitioners; Physician Assistants
|1.||Establish differential diagnosis for chronic migraine in accordance with the ICHD-III beta criteria and evaluate risk for transitioning from episodic to chronic migraine||2.||Employ validated clinical tools to evaluate migraine-related disability, set treatment goals, and monitor treatment response, including patient adherence to therapy|
|1.||Establish differential diagnosis for chronic migraine in accordance with the ICHD-III beta criteria and evaluate risk for transitioning from episodic to chronic migraine|
|2.||Employ validated clinical tools to evaluate migraine-related disability, set treatment goals, and monitor treatment response, including patient adherence to therapy|
Statement of Need
According to the 2010 Global Burden of Disease Study, headache represents one of the top 10 causes of disability, and migraine, in particular, is responsible for 3% of disability attributable to a specific disease. Although most headache patients are managed in the primary care setting, chronic headache remains the most common cause of neurological consultation. In the United States, the American Migraine Prevalence and Prevention (AMPP) study reported an overall prevalence of migraine headache of 11.7%, probable migraine of 4.5%, and chronic migraine (CM) of 1%. CM represents a more disabling and difficult-to-treat disorder than episodic migraine (EM). It is also the most common form of chronic daily headache seen in US clinics. Yet CM is an underdiagnosed and undertreated disorder; only 20%-25% of patients who meet the criteria for CM receive appropriate diagnosis today.
CM can be considered a complication of EM with more frequent attacks and fewer pain-free intervals. The AMPP study found that compared with EM patients, CM patients have doubly higher rates of depression, anxiety, and chronic pain. Other disorders that are often seen in CM patients include respiratory disorders, cardiac risk factors, diabetes and obesity. Notably, as demonstrated by recent studies, appropriate preventive treatment for CM might lessen headache disability, associated comorbidities, and improve health-related quality of life. Since an increasing number of CM patients present to neurology and pain specialists, it is of key importance that these health care providers are kept up-to-date with evidence-based best practices in establishing correct diagnosis for CM and choosing appropriate multimodal treatment strategies.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and HealthmattersCME. Global is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org
Fee Information and Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient-care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Stephen D. Silberstein, MD, Chair
Nothing to disclose
David W. Dodick, MD
Consultant/Independent Contractor: Alcobra; Alder; Allergan; Amgen; Arteaus; Autonomic Technologies; Boston Scientific; Bristol-Myers Squibb; Colucid; Electrocore; Eli Lilly & Company; ENeura; Ethicon J&J; Impax; Labrys; Lundbeck; MAP Pharmaceuticals; Medtronic; Merck; Novartis; NuPathe; Pfizer; St Jude; Supernus; Teva; Tonix; Zogenix
Alcobra; Alder; Allergan; Amgen; Arteaus; Autonomic Technologies; Boston Scientific; Bristol Myers Squibb; Colucid; Electrocore; Eli Lilly & Company; ENeura; Ethicon J&J; Impax; Labrys; Lundbeck; MAP Pharmaceuticals; Medtronic; Merck; Novartis; NuPathe; Pfizer; St Jude; Supernus; Teva; Tonix; Zogenix
Allergan; American Academy of Neurology; Decision Resources; Healthlogix; IntraMed; John Wiley & Sons, Inc; Oxford University Press; SAGE Publishing; Starr Clinical; Sun Pharmaceuticals; Synergy; Universal Meeting Management; UptoDate; WebMD
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Nothing to disclose
Amanda Glazar, PhD
Nothing to disclose
Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and HealthmattersCME do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Instructions for Receiving Credit
In order to receive credit for this activity, the participant must review the content, complete the post-test with a passing score of 70% or higher, and complete the evaluation form.
This activity is jointly provided by Global Education Group and HealthmattersCME.
This activity is supported by an independent educational grant from Allergan.
COURSE VIEWING REQUIREMENTS
|Supported Browsers: |
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above
For video playback, install the latest version of Flash or Quicktime.